Preferred Label : belzutifan;

MeSH hyponym : MK6482; PT2977;

UNII : 7K28NB895L;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/welireg
2025
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
administration, oral
belzutifan
belzutifan
belzutifan
antineoplastic agents
antineoplastic agents
HIF-2alpha Inhibitor
HIF-2alpha Inhibitor
risk management
product surveillance, postmarketing
clear cell renal cell carcinoma
Advanced Clear Cell Renal Cell Carcinoma
Refractory Clear Cell Renal Cell Carcinoma
adult
von Hippel-Lindau disease
Central Nervous System Hemangioblastoma
carcinoma, renal cell
Pancreatic Neuroendocrine Tumor
Unresectable Pancreatic Neuroendocrine Tumor
EPAS1 protein, human
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical

---
https://www.cadth.ca/fr/belzutifan
2023
false
false
false
Canada
French
English
drug evaluation
canada
belzutifan
belzutifan
von Hippel-Lindau disease

---
Nous contacter.
15/06/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.